Medication Harm: America’s Silent Epidemic and How Personalized Medicine Can Help

Every day, people trust that the medications prescribed to them will heal, relieve, or prevent the ailments they face. Instead, for hundreds of thousands of Americans, these same medications contribute to harm. Recent analyses indicate that adverse drug events — harmful reactions related to medications — have now risen to become the third leading cause of death in the United States, behind heart disease and cancer. This staggering finding underscores a public health crisis that has largely flown under the national spotlight.^1,2 

Understanding the Scope

An adverse drug reaction (ADR) occurs when a medication produces an unintended and harmful effect at normal dosing. These are not rare events. Estimates from the latest data show millions of adverse events annually, with hundreds of thousands leading to emergency visits, hospitalizations, and death.³ 

The reasons behind this crisis are complex. They include medication errors, drug-drug interactions, and genetic differences in how individuals metabolize drugs. These genetic differences are especially important because identical prescriptions can behave very differently across patients. For example, variations in drug-metabolizing enzymes or drug transporter genes can render some medications ineffective or toxic in certain individuals.⁴ 

Why the Current Practice Falls Short

In today’s standard approach to medication, prescriptions are often based on broad clinical guidelines, with limited consideration of individual variability. Two patients with the same condition might take the same drug at the same dose, yet one might benefit while the other experiences severe side effects. This variability is a core driver of ADRs and highlights a key missing piece in many treatment plans: personalized insight into how a specific patient’s biology will interact with medication. 

Pharmacogenomics: A Path Forward

This is where pharmacogenomics (PGx), the study of how genes influence drug response, comes into play. By analyzing a person’s DNA, clinicians can better understand how a medication will be metabolized or whether a person is at heightened risk of an adverse reaction. Clinical evidence shows that pharmacogenomic information can significantly lower the occurrence of ADRs and improve treatment safety.⁵ 

Research across large clinical cohorts has shown that patients guided by genetic insights experienced fewer adverse drug reactions than those in standard care. In practical terms, PGx testing can reduce medication-related harm by helping clinicians select drugs that are more likely to be safe and effective for each patient.⁶

Kadance’s Medication Optimization Program

Kadance recognizes medication safety and optimization as a cornerstone of proactive health management. Our Medication Optimization Program integrates advanced pharmacogenomic testing with individualized care guidance. Through this program, members gain access to insights that inform safer, more effective medication choices informed by their unique genetic profile and clinical history. The goal is straightforward: reduce the risk of ADRs before they happen.

Unlike traditional medication management, which treats “one size fits all,” Kadance’s approach helps clinicians and members anticipate medication risks and adjust treatment plans accordingly. This isn’t just about avoiding side effects; it’s about empowering individuals and health professionals with proactive tools that promote better health outcomes and reduce unnecessary suffering and costs from preventable medication harm.

Moving Toward Safer Prescribing and Better Outcomes

The data are clear: medication-related harm is a leading cause of death and a patient's unique genetic makeup plays a significant role in how they respond to treatments. Integrating pharmacogenomics into routine care, especially for populations on multiple medications or with complex medical histories, represents a promising advance in patient safety and outcomes.

Programs like Kadance’s Medication Optimization Program not only enhance care personalization but can help reduce the human and economic toll caused by adverse drug reactions. As science advances, so should our approach to medication safety, with precision, prevention, and patient-centered care at the forefront.

‍

Resources:

¹PR Newswire. (2025, March 24). America's Silent Epidemic Worsens: Adverse Drug Events Now the Third Leading Cause of Death. Accessed January 7, 2026. https://www.prnewswire.com/news-releases/americas-silent-epidemic-worsens-adverse-drug-events-now-the-third-leading-cause-of-death-302408765.html

²Practical Neurology. (2025, March 26). New Analysis Suggests Adverse Drug Events Are the 3rd Leading Cause of Death in the USA. Accessed January 7, 2026.